---
document_datetime: 2023-09-21 17:21:40
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/scientific-conclusion/venclyxto-epar-conclusions-granting-conditional-marketing-authorisation_en.pdf
document_name: venclyxto-epar-conclusions-granting-conditional-marketing-authorisation_en.pdf
version: success
processing_time: 0.7432872
conversion_datetime: 2025-12-30 10:27:42.051926
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ANNEX IV

Conclusions on the granting of the conditional marketing authorisation presented by the European Medicines Agency

<div style=\"page-break-after: always\"></div>

## Conclusions presented by the European Medicines Agency on:

## Â· Conditional marketing authorisation

The CHMP having considered the application is of the opinion that the risk-benefit balance is favourable to recommend the granting of the conditional marketing authorisation as further explained in the European Public Assessment Report.